Fresh explant culture of human tumours in vitro and the assessment of sensitivity to cytotoxic chemotherapy. by Berry, R. J. et al.
Br. J. Cancer (1975) 31, 218
FRESH EXPLANT CULTURE OF HUMAN TUMOURS IN VITRO
AND THE ASSESSMENT OF SENSITIVITY TO
CYTOTOXIC CHEMOTHERAPY
R. J. BERRY*, A. H. LAING AND J. WELLS
From the Churchill Hospital Research Institute and Department of Radiotherapy,
Churchill Hospital, Oxford
Received 19 August 1974. Accepted 3 October 1974
Summary.-Ninety-seven fresh explants of human tumours have been cultured in
vitro in an attempt to predict their sensitivity to subsequent cytotoxic chemotherapy.
Only 3/26 solid ovarian tumours were cultured successfully although 12 of the 23
which failed to grow proved later to have benign histology. Of 10 solid tumours
from other sites, only2/4 renal tumours and one melanoma were successfully grown
and tested in vitro. A higher success rate was achieved inculturing carcinoma cells
of ovarian (10/22) and breast (10/22) origin from ascitic and pleural fluids. Using
increase in cell number after 7 days' growth in vitro as the biological end-point,
concentrations of cytotoxic drugs which are achievable in patients produced sig-
nificant effects on some tumour explants. Detailed studies of serial subcultures
in vitro from an ovarian tumour showed that large changes in chemosensitivity
occur within about 2 passages in vitro, so that sensitivity testing can only be carried
out using fresh explants or their first subcultures if any possible correlation between
in vitro cytotoxicity and in situ response is to be studied. Clinical effectiveness
and in vitro chemosensitivity are compared for a limited number of patients with
ovarian and breast carcinomata for whom follow-up information was available;
no useful correlation was found.
Tms PAPER presents the results of
the first 25 months' efforts in this labora-
tory to predict their subsequent response
in vivo to cytotoxic chemotherapy by
studies of fresh explants of human
tumours in vitro. Obtaining tumour
samples in no case required that the
patients underwent any procedures other
than those normally needed for their
diagnosis and treatment.
As early as 1957, correlations were
claimed between the responses of human
tumours in tissue culture and their
subsequent response in situ to cytotoxic
chemotherapy (Wright et al., 1957). A
number of different biochemical and
cytological end-points have been chosen
for such studies and extremely high levels
of agreement have been claimed between
the results obtained in vitro and those
in the patient (e.g. Sky-Peck, 1964;
Limburg, 1969). Other authors have
been more cautious (e.g. Wolberg, 1971)
and recent detailed studies of a spon-
taneous murine mammary carcinoma have
shown little or no agreement between in
vitro and in vivo activity of several
cytotoxic drugs (Balconi et al., 1973).
The most comprehensive studies ofchemo-
sensitivity testing in vitro which have
been carried out in the U.K. have been
those of Dendy and his collaborators at
Cambridge. This group has used as its
biological end-point the short-term in-
corporation into DNA of radioactively
labelled precursors after exposure to the
cytotoxic agent (Mitchell et al., 1971).
In the present study, we have attempted
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to use the biological end-point most
closely related to the desired clinical
response (the failure of tumour cells to
grow after exposure to the cytotoxic
drug) and have limited the concentrations
of drugs used to those which can be
achieved in patients without producing
life threatening side-effects.
MATERIALS AND METHODS
Culture of tumour cells from ascites and
pleural fluid.-The aspirated fluid (about
500 ml) was centrifuged gently (30 g for
5 min at room temperature) and the packed
cell layer (or the " buffy coat" when large
numbers of red cells were present in the
fluid) was resuspended in complete growth
medium consisting of Medium 199 (Morton,
Morgan and Parker, BDH) supplemented
with 15% type AB human serum plus
penicillin and streptomycin. The cells were
counted electronically using a Coulter Model
D counter with a 140 ,um orifice. This
counter was calibrated against cells of
different sizes using a haemacytometer.
Appropriate dilutions were made so that a
total of 1 x 104 or 1 x 105 cells would be
contained in 4 ml of complete growth
medium, and this volume was placed in
each of several 25 cm3 Falcon TC poly-
styrene flasks. Humidified 5% C02/95%
air was bubbled through the flasks to
equilibrate the growth medium to pH 7, and
the flasks were then sealed and incubated
at 370C in a horizontal position to allow
cell attachment and growth. The cultures
were inspected periodically under phase-
contrast with the inverted microscope for
the growth of tumour cells of epithelioid
morphology. Cultures were discarded if no
growth was seen within 2 weeks, if they
became infected, or if they showed fibro-
blastic growth typical of the proliferation
of normal cells of connective tissue origin
(both rare occurrences). After incubation,
the growth medium was gently poured off
and floating cells counted. A volume of
5 ml of 0-1% w/v trypsin (Bacto-Trypsin,
Difco) solution, made isotonic with sodium
citrate was added to the flask and incubated
for 5 min at 370C. The flask was then
shaken vigorously to dislodge any remaining
attached cells and the trypsin solution
diluted as necessary with complete growth
medium so that the cells could be counted
in the Coulter counter (attached cells).
If the culture was to be propagated serially, 104 or 105 cells contained in 5 ml ofcomplete growth medium were re-inoculated into a
culture flask as for the primary culture.
Culture of cells from solid tumours.-The
biopsy or operative specimen was quickly
chopped with fine sterile scissors into pieces
less than 1 mm3. These were then covered
with 5 ml of a 0.1% w/v solution of trypsin
as described above and incubated at 370C
for 15 min. An equal volume of complete
growth medium was added and the fluid was
centrifuged gently at 30 g for 5 min at room
temperature. The tumour cells (and remain-
ing pieces) were resuspended in 5 ml of com-
plete growth medium and the cell suspension
carefully decanted off, diluted as necessary
with complete growth medium and the cells
counted in the Coulter counter. If large
numbers of free tumour cells had been
obtained, the cell suspension was handled
exactly as were those from malignant ascites
or pleural effusions, and 104 or 105 cells
contained in 4 ml ofcomplete growth medium
placed in the culture flasks. If, however,
the initial cell count was low, the cell suspen-
sion and remaining tumour pieces were
recombined, shaken and 5 ml aliquots
placed in 2 culture flasks which were gassed
with 5% CO2/95% air, sealed and incubated
at 370C. If after 4-7 days significant
growth of epithelioid cells could be seen,
the flasks were shaken vigorously to dislodge
the remaining tumour pieces, the medium
was poured off and replaced with fresh
complete growth medium and the flasks re-
incubated and treated thereafter the same
as cultures obtained from ascites or pleural
fluid.
Preparation and addition of cytotoxic
drugs.-The drugs which were used were
chosen because of their common use, or
projected use, alone or in combination, in
the treatment of advanced malignant disease
in Oxford. These are shown in Table I.
All drugs were freshly prepared before
adding to the final volume of complete
growth medium containing the tumour cells
to be tested. With the exception of chlor-
ambucil, all the drugs used were diluted in
sterile distilled water; chlorambucil is in-
soluble in water and was diluted in dimethyl-
sulfoxide (DMSO) before being added to
complete growth medium containing the
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TABLE I.-Cytotoxic Drugs Studied
Mechanism Usual maximum dose Concentration in complete
of cytotoxic for 70 kg patient growth medium*
Drug action (mg) (pg/ml)
Chlorambucil (Wellcome) Alkylating agent 10 0-2
Thio-TEPA (Lederle) Alkylating agent 30 0-6
Vincristine (Lilly) Mitotic poison 2 0-04
5-Fluorouracil (Roche) Antimetabolite 1000 20
Methotrexate (Lederle) Antimetabolite 5 0-1
* This concentration is approximately equal to the maximum drug concentration likely to be achieved
in body fluids of a patient after administration of the usual maximum dose.
tumour cells. When this drug was tested,
an additional control flask was prepared
containing an equivalent amount of DMSO
(0-02 ml/ml growth medium) but no chlor-
ambucil. After addition of the drug to be
tested, the flasks were incubated for 7 days
at 370C without agitation or change of
medium, and the floating and attached cells
then counted as described. The choice of
a 7-day incubation period resulted from the
observation that rapid growth usually ceased
by about 5 days after initiation of the
cultures, whilst a decrease in total cell
number due to exhaustion of the growth
medium rarely occurred before 12 days;
the 7-day period represented very nearly
the maximum growth and was a time at
which only small errors might be introduced
by up to 8 h variations in total incubation
time due to counting the cultures at different
times in the working day.
RESULTS
The sites of origin of the tumours
studied and the rates of success in obtain-
ing primary cultures and chemosensitivity
testing are summarized in Table II.
TABLE II.-Summary ofPrimary Cultures Obtained and Chemosensitivity
Tests Completed
Site of origin
1. Solid tumours
Ovary
Kidney
Breast
Melanoma
Bladder
Hodgkin's disease
Total
2. Pleural effusions
Breast
Ovary
Seminoma
Reticulum cell sar.
Stomach
Pancreas
Unknown 10
Total
3. Malignant ascites
Ovary
Breast
Colon
Hodgkins/lymphoma
Bronchus
Stomach
Pancreas
Teratoma
Total
Successful
No. of primary
samples cultures
26*
4
3
1
1
1
36
16
4
3
2
1
1
1
28
18
6
3
2
1
1
1
3
2
0
1
0
0
6
Successfully tested against:
Chlor.
1
1
5
2
1
0
0
0
0
8
4
2
8
5
1
2
1
0
0
1 0
33 17
Thio-
TEPA Vinc. 5-FU MTX
1 2
- 2 2
1 1
3
1
3
1
1
3
1
1
4 7 7 3
4 4 -
1 2 2
1 1 1
* Twelve of these ovarian tumours proved subsequently to have benign histology; successful primary
cultures were obtained only from malignant ovarian tumours.
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Primary cultures were regarded as suc-
cessful if the total number of tumour
cells at any time exceeded the number
of cells with which the flasks had been
inoculated. Of the 31 successful primary
cultures, chemosensitivity tests against
one or more drugs were achieved in the
vast majority (24). Only limited success
was achieved in establishing primary
cultures from solid tumours; even if 12
of the 26 ovarian tumours which later
proved to have benign histology are
excluded, only 6/24 showed net increase
in cell number in vitro under our culture
conditions. Better results were obtained
with cultures from malignant pleural
effusions and ascitic fluid. The 7-day
growth achieved after plating freshly
explanted tumour cell inocula of 104 or
105 cells from carcinomata of the ovary
and breast are shown in Table III.
In contrast to the relatively good initial
growth shown by the breast tumour
cells, and of the cells derived from the
TABLE III.-Chemosensitivity ofFresh Explant Cultures ofHuman Tumours
7-day (control)
growth
At-
tached
Origin of cells
Patient sample x 105
I. Carcinoma of the ovary
(a) 105 Tumour cells plated
G.L. Solid tumour 4-5
J.B. Solid tumour 7- 1
L.W. Pleural fluid 1.1
E.W. Ascites 0 05
K.H. Ascites 0-41
A.C. Ascites 0 43
I.O. Ascites 0-74
J.H. Ascites 0 71
(b) 104 Tumour cel1s plated
L.W. Pleural fluid 0.11
E.W. Ascites 0 07
K.H. Ascites 0 11
A.C. Ascites 0 02
I.O. Ascites 0-16
J.H. Ascites (1) 0-21
J.H. Ascites (2) 0 17
I.L. Ascites 0- 17
II. Carcinoma of the breast
(a) 105 Tumour cells plated
J.B. Pleural fluid 9 1
G.T. Pleural fluid 13-1 1
D.S. Pleural fluid 5-8
P.T. Ascites 4-4
R.B. Ascites 6-5
B.C. Ascites 2-7
C.W. Ascites 8-8 ]
(b)
J.B.
P.T.
R.B.
B.C.
104 Tumour cells plated
Pleural fluid 8-3
Ascites 1 1
Ascites 1- 2
Ascites 1- 6
Total
cells
X 105
4.9
10-5
3.5
0-17
1-7
1.1
1-7
1.0
0-13
0-14
0-31
0-10
0-26
0 56
0 22
0-27
11 2
13*5
6-1
5 8
9 6
3-2
10-0
9.4
1-5
2-0
2-4
Percentage of control growth
r-
A
Chlor-
ambucil
Att. Total
cells cells
54
0loo
85
92
53
"1OO >'oo
84
29 43
o100 100
Si1oo 20
58 S100
84 87
100 100
70 83
Thio-
TEPA
, T
Att. Total
cells cells
76 87
Vin-
cristine
Att. Total
cells cells
6
15
100
97
93
95
80
23
19
>100
83
98
0loo
>100
- 90 14
21 86
' 100 S 100
- - 64 58
- - 67 S 100
- - 62 > 100
100 S100 58 96
82 S100 - -
76 , 100 73 63
47
82
72
37
78
85
75
43
16
30
23
31
50
37
15
10
69
57
55
33
37
27
47
62
43
20
12
74
68
71
5-Fluoro-
uracil
Att. Total
cells cells
Metho-
trexate
Att. Total
cells cells
18
9
23
80
63
59
97
54
43
30
26
s100
60
0loo
> 100
S100 22 S:i'oo Soo
50 74
86 100
67 88
42 89
76 S 100
67 100
82 S 100
24 41
17 33
45 47
29 32
66 89
27 44
22 32
25 30
29 28
66 94
64 76
48 ,100
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Serial Passage Number
0 2 4 6 8 10 12
Cells
Patient E. W.,
D103 - Carcinoma of the Ovary (Asc
FIG. 1. Growth in 7 days following inocula-
tion of 105 tumour cells at explantation and
at subsequent serial passage in vitro of cells
from an ovarian carcinoma (Patient E.W.)
showing chaniging response to addlition of
vincristine, 0 * 04 jig/ml to the growth
medium.
ites)
2 solid ovarian tumours, the primary
cultures of ovarian tumour cells from
ascitic and pleural fluid showed very low
cell numbers after 7 days' incubation.
Because of this, ascites tumour cells
from one patient with carcinoma of the
ovary (E.W.) were passaged serially in
vitro to see whether better growth could
be obtained and whether chemosensitivity
testing could be undertaken satisfactorily
when such improved growth was ob-
served. Figure 1 shows the number of
tumour cells harvested from an inoculum
of 105 cells after 7 days' incubation at
the primary culture of these tumour
cells and after 1, 2, 4 and 12 serial passages
at which the cells were trypsinized,
counted and re-plated in fresh complete
growth medium At the first and second
subculture, the number of tumour cells
harvested increased dramatically but
thereafter tumour cell growth remained
approximately constant Other data for
cultures initiated with 104 tumour cells
showed that the number of tumour
cells harvested after 7 days' growth
remained constant from the second to
the 29th serial subculture The pro-
liferation of these tumour cells during
this period of apparently stable growth in
vitro is shown in Fig. 2; the tumour cell
population doubled every 37 h, until a
plateau was reached due to overcrowding
and nutritional inadequacies ofthe growth
medium Karyotype analysis of these
tumour cells at several subcultures showed
that they were aneuploid, with a modal
chromosome number in the upper 50s.
Figure 1 also shows the number of cells
harvested after 7 days' growth in cultures
to which vincristine (0.04 ,ug/ml) had
been added. Note that even during the
period of apparently stable growth from
subcultures 2-12 there is a large increase
in the sensitivity of the tumour cells to
this drug. That this appears to be a
general phenomenon is shown in Fig. 3,
in which %O of control growth in 7 days
in cultures treated with an alkylating
agent (thio-TEPA), a mitotic inhibitor
(vincristine) and an antimetabolite
(5-fluorouracil) is plotted against the
number of serial subcultures since ex-
plantation of the tumour cells. Data are
shown for cultures initiated with 104 or
with 105 tumour cells. It is clear that
the chemosensitivity of these freshly
explanted tumour cells changes rapidly
with serial subculture and that at least
part of this change in sensitivity is not
associated with any change in the rate
of overall cell growth in vitro under the
conditions we have used.
The results of chemosensitivity testing
of our largest series of similar tumours,
9 patients with ovarian carcinomata and
7 with carcinoma of the breast, are
shown in Table III. A summary of the
clinical course of those in whom relevant
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FIG. 2. Growth in vitro following inoculation of 105 tumour cells from an ovarian carcinoma
(Patient E.W.) at its 4th serial passage in vitro. Total cells represent the sum of attached cells
and floating cells (see text). Note that there is no significant change in the number of cells in
the culture from 6-10 days.
follow-up information was established is
shown in Table IV.
DISCUSSION
Initial culture
The results obtained by culturing
trypsinized pieces of solid tumours are
disappointing; we have therefore con-
centrated more recent effort in this
laboratory upon improvement in tech-
niques to attempt to increase the number
of successful primary explant cultures
from solid tumours and to increase the
proportion of clonogenic cells in those
cultures (Wells, personal communication).
By contrast, the high initial success
rate with cultures of malignant ascites
and pleural effusions seems unlikely to
be raised dramatically by alterations in
culture methods.
Tumour cells originating from different
primary sites showed quite different
patterns of growth in explant culture;
cells from malignant ascites due to
carcinoma of the ovary evinced little
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Patient E W., Carcinoma of the Ovary (Ascites)
Inn-4
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Serial Passage Number
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I I I I* * a
....,Attached
Thio-TEPA,
104 tumour cells plated
Tota,
...,Attached
Vincristine,
10 tumour cells plated"'
Total
° .... ,Attached
5-Fluorouracil,
104 tumour cells plated
100 -
10 -
10-
Serial Passage Number
u 2 4 6 8 10 12
°
-
Total
Attached
IThio-TEPA,
105 tumour cells plated
.4. .
*Total
Attached'*..
Vincristine,
105 tumour cells plated A
5-Fluorouracil,
10 tumour cells plated
FIG. 3.-Decrease in 7-day growth of cells from an ovarian carcinoma (Patient E.W.) exposed to
thio-TEPA (0-6 ,g/ml), vincristine (0.04 4uglml) or 5-fluorouracil (20 ,ug/ml) immediately after
explantation and after serial passage of the tumour cells in vitro.
overall increase in number during a
7-day period whereas ascitic cells from
carcinoma of the breast showed 3-to-13-
fold overall growth in the same period.
On serial subculture, however, the rate
of growth of ascitic tumour cells from
one ovarian carcinoma increased rapidly
to reach a stable plateau by their second
trypsinization (Fig. 1), which differed
little from the total growth seen in ascitic
cells from breast carcinomata at their
initial explantation.
.-
0
C
0
L-)
0
C.
L.
0~
224
ivuIF
-
-
I
-
IFRESH EXPLANT CULTURE OF HUMAN TUMOURS IN VITRO
TABLE IV. Clinical Status ofPatient8 Whose in vitro Chemosensitivity is
Detailed in Table III
Patient Treatment I
1. Carcinioma of ovary
G.L. Thio-TEPA, Nil
Chlorambucil,
Vincristine,
5-Fluorouracil
L.W. Chlorambucil, >5
Vincristine, vol
5-Fluorouracil redi
E.W. Chlorambucil, > 5
Vincristine, vol
.3-Fluorouracil redi
A.C. Chlorambucil, Tot
Vincristine, pea
5-Fluorouracil turr
J.H. (1) Chlorambucil Tur
no
(2) Thio-TEPA Nil
given
sequentially
I.L. Thio-TEPA, <3(
Vincristine, Volt
5-Fluoroturacil Ieedl
Length
of
Tumour Irespolnse
response (mths)
Clinical
Death response
(mths) rank*
5 6
iO% tumour
ume
uction
iO% tumour
ume
uction
tal disap-
trance of
nour
mour held,
growth
iO% tumour
ume
uction
5 9 2
4 7 3
22 Alive 1
4
16
2 15 5
50 ° in vitro growth
inhibition
Thio-
Chlor. TEPA Vinc. 5-FU MTX
Yes
- -- Yes Yes
Yes Yes No No -
(±) (±)
Yes No No --
(i)
No No Yes
($)
No
No No No Yes
2. Carcinoma of the breast
J.13. (1) 5-Fluorouracil >500% tumour
volume
reduction
(2) Thio-TEPA,
Vincristine,
Methotrexate
B.C. Thio-TEPA
(only 1 pulse)
C.W. Vincristine,
5-Fluorouracil,
Methotrexate
Tumour held,
no growth
Nil
7 1.5 1
4 4
2
2
3
- Yes
(±)
No
No
Yes Yes
Yes Yes
(±) (±)
- Yes Yes
* Ranked in order from 1 = best clinical response.
Growth inhibition listedl as Yes (±) when either attached or total cells but not both show >50% de-
pression, or where > 50% depression observed with cultures of 104 or lQ5 cells but not both.
Chemosensitivity in vitro of fresh explant
cultures from carcinomata of the ovary and
breast
In most cases, the total number
of cells per culture flask was affected
less than was the number of attached cells
by exposure to the chemotherapeutic
agents used in these experiments. The
variations observed between results ob-
tained in cultures initiated with either
104 or 105 tumour cells, and the limited
number of results with multiple repeat
flasks where the initial cell numbers were
large enough to permit this suggested
that only differences in cell number of
the order of a factor of 2 indicated
significant differences in tumour cell
growth rather than experimental varia-
tion. Therefore, if a cell culture to
which a drug has been added contained
>5000 of the number of cells to be found
in the control culture at the end of the
7-day incubation period, little confidence
can be attached to the cytotoxicity of
this drug in vitro. The confidence limit
is large because in most cases the number
of replicate cultures is insufficient for
rigid statistical analysis and this pessi-
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mistic confidence limit is a measure of
the maximum observed variation.
Change in tumour cell chemosensitivity with
serial culture in vitro
The results obtainecd with serially
propagated cultures from patient E.W.
(Fig. 1-3) make it clear that whether or
not due to selection by the culture condi-
tions chosen, the chemosensitivity of
tumour cells changes rapidly with time
in culture. Some ofthe changes observed
may be correlated with the increased
growth seen at first and second sub-
culture of cells from malignant ascites
due to ovarian carcinoma, but further
increase in chemosensitivity is seen with
subsequent subcultures even when a
stable rate of growth in vitro has been
achieved. Although there are quantita-
tive differences, the picture was largely
similar for cultures initiated with 104
cells and those started with 10O tumour
cells. Further detailed experiments are
in progress in this laboratory to ascertain
whether the rapid change in chemo-
sensitivity of freshly explanted ovarian
tumour cells is common to tumour cells
of other origins (Wells, personal com-
munication). These rapid changes, how-
ever, make it likely that chemosensitivity
testing in vitro which actually reflects
tumour chemosensitivity in situ will only
be achieved if at all with fresh tumour
explants challenged with the cytotoxic
agents as soon as possible after their
removal from the bodv.
Correlation of clinical response with chenmo-
sensitivity testing in vitro
A disappointingly small number of
patients received chemotherapy with
drugs that had been previously used in
the in vitro tests. Of 9 patients with
ovarian carcinomata, 2 died without
receiving chemotherapy and another died
of pulmonary embolism within 2 weeks.
Of the remaining 6, 4 showed good or
moderate objective response to chemo-
therapy while 2 showed no response only
one of the former would have been pre-
dicted to do well because of a >500o
depression in 7-day tumour cell growth in
vitro from any of the drugs tested, while
one of the 2 patients who did badly
showed considerable in vitro cell killing
from the one drug tested. The results
among the 7 patients with carcinoma of
the breast are even less encoutraging:
only 3 patients actually received chemo-
therapy. By in vitro criteria, 2 of these
patients would have been expected to
show good tumour response one did
so but the other showed no objective
response to the same chemotherapeutic
agents. It is clear that far larger numbers
of patients must be studied, using con-
sistent culture techniques in vitro, before
any reliable assessment can be made of
the predictive value of in vitro chemo-
sensitivity testing for subsequent tumour
response. Individual centres should con-
centrate their efforts upon tumours in
a limited number of sites if the maximum
amount of useful information is to be
obtained. It is our intention in Oxford
to concentrate upon carcinomata of the
ovary, as part of a prospective clinical
trial of the management of this disease
which is now underwav.
The results presented here, however,
offer little assurance that chemosensitivity
testing in vitro of freshly explanted
human tumours will allow dramatic im-
provement in the prognosis of patients
with disseminated malignant disease whose
only therapeutic hope at present is
cytotoxic chemotherapy.
Since this paperwas submitted, Holmes
and Little (1974) have published results of
the use of a tissue-culture microtest for
predicting response of human tumours to
chemotherapy. Their criterion of cell
viability was the number ofcells remaining
after 72 hours' exposure to the cytotoxic
agents or hormones tested. They report a
higher success rate for primary cultures
and a better correlation with clinical re-
sponsethan we have achieved intheresults
presented here.
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